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doi:10.1016/j.jtcvs.2005.11.030bjective: To determine the feasibility and safety of skeletal myoblast transplantation
n patients with chronic myocardial infarction undergoing coronary artery bypass
rafting.
ethods: Twelve patients with a previous myocardial infarction and ischemic
oronary artery disease underwent treatment with coronary artery bypass grafting
urgery and intramyocardial injection of autologous skeletal myoblasts cultured
ith autologous serum. Global and regional cardiac function was assessed by echo-
ardiogram. Fluorine 18 fluorodeoxyglucose and nitrogen 13–ammonia positron emis-
ion tomography studies were used to determine cardiac viability and perfusion. A
roup of historical control patients (n  14) treated with coronary artery bypass
rafting surgery without myoblast transplantation was analyzed.
esults: The left ventricular ejection fraction improved from 35.5%  2.3% (mean 
EM) before surgery to 55.1%  8.2% at 12 months (P  .01) in the myoblast group
nd from 33.6%  9.3% to 38.6%  11% in the control group. Regional contractility
lso improved in the myoblast group, particularly in cardiac segments treated with
keletal myoblasts (wall motion score index: 3.02  0.17 at baseline vs 1.36  0.14 at
2 months; P  .0001). Quantitative fluorine 18–fluorodeoxyglucose and nitrogen
3–ammonia positron emission tomography showed an increase in viability and perfu-
ion 12 months after surgery both globally and in segments treated with myoblasts (P
.012 and P .004). Skeletal myoblast implantation was not associated with adverse
vents or an increased incidence of cardiac arrhythmias.
onclusions: In patients with previous myocardial infarction, treatment with skeletal
yoblasts in conjunction with coronary artery bypass is safe and feasible and is
ssociated with an increased global and regional left ventricular function, improvement
n viability, and perfusion of cardiac tissue and no significant incidence of arrhythmias.
ardiac failure due to ischemic cardiomyopathy is one of the major health
problems in the world because of its high prevalence and the high mortality
and morbidity associated with it.1 Myocardial infarction (MI) is associated
ith an irreversible loss of cardiomyocytes that leads to a process of cardiac
emodeling with left ventricular (LV) enlargement and abnormal contractility that
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 4 799
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CSPventually results in cardiac failure.2 Although in the last
ew years several studies have suggested that the heart may
ave a certain capacity for regeneration, this is by no means
nough to restore a normal function after MI.3,4
Cell therapy has emerged as a potential alternative to
eart transplantation for patients with end-stage cardiac
isease.5 With the aim of replacing necrotic tissue, cells
rom different sources have been implanted in animal mod-
ls of MI, including embryonic stem cells,6 fetal cardiomy-
cytes,7 skeletal myoblasts,8 hematopoietic stem cells,9
esenchymal stem cells,10 or endothelial progenitor cells.11
ost of these studies have invariably shown engraftment of
onor cells and reconstitution of heart structures, ie, cardi-
myocytes and blood vessels, and most of them have been
ssociated with improved heart function. The results from
linical trials of intramyocardial cell transplantation with
one marrow mononuclear cells12,13 or bone marrow– de-
ived AC133-positive cells14 for cardiac regeneration have
een recently reported.
Among the different cell types used, skeletal myoblasts
ave several advantages: increased resistance to ischemia,
utologous origin, ready access to the cell source, and the
easibility of ex vivo expansion of progenitor cells.15,16
owever, the initial clinical studies have suggested that
ransplantation of skeletal myoblasts in patients with MI
ay be associated with an increased incidence of cardiac
rrhythmias.17,18
In this study, we have analyzed the results at 1 year in a
roup of patients with a history of MI treated with coronary
rtery bypass grafting (CABG) and skeletal myoblast trans-
lantation. The safety of the procedure and its functional
esults were assessed by echocardiography, whereas perfu-
ion and viability were determined by nitrogen 13 (13N)-
mmonia and fluorine 18 –fluorodeoxyglucose (18F-FDG)
ositron emission tomography (PET) studies and compared
ith a historical control group of patients treated with
ypass surgery alone.
atients and Methods
atient Population and Study Design
total of 12 patients were included in the study. Inclusion criteria
ere (1) a history of MI greater than 4 weeks previously with
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
18F-FDG  fluorine 18–fluorodeoxyglucose
LV  left ventricle
LVEF  left ventricular ejection fraction
MI myocardial infarction
PET  positron emission tomography
WMSI  wall motion score indexkinetic or dyskinetic nonviable scar tissue, as demonstrated by a T
00 The Journal of Thoracic and Cardiovascular Surgery ● Apriack of metabolic activity on 18F-FDG PET; (2) indication for
lective CABG; (3) age 30 to 80 years; and (4) a LV ejection
raction (LVEF) greater than 25%. Exclusion criteria included
1) an inability to obtain a myoblast cell culture, (2) a positive
erologic test for human immunodeficiency virus or hepatitis,
3) a history of malignant arrhythmia or muscular dystrophy, and
4) abnormal liver or kidney function tests. The protocol and all the
rocedures were approved by the Institutional Review Board for
uman Studies and Ethics Committee, the Regional Review Board
or Clinical Trials With Human Subjects, and the Spanish Health
uthorities. All patients signed an informed consent before enter-
ng the study.
Before surgery, all patients underwent 13N-ammonia and 18F-
DG PET scanning, echocardiography, and 24-hour Holter mon-
toring to determine the functioning and viability of the heart
uscle. Laboratory studies included cardiac and liver enzymes and
-reactive protein. Studies were repeated 3 and 12 months after
urgery. The preliminary results at 3 months have been reported
reviously.19
A control group of 14 matched patients who met the same
nclusion criteria and received the same treatment, including by-
ass surgery, but who did not receive skeletal myoblast transplants
ere analyzed. This group underwent the same functional studies
xcept for PET analysis.
chocardiography Studies
lobal and regional myocardial contractility was measured by
-dimensional echocardiography by using a Sonos 5500 ultra-
ound system (Philips Medical Systems, Irvine, Calif). Regional
V wall motion analysis was performed as described by the
ommittee on Standards of the American Society of Echocardi-
graphy,20 by dividing the LV into 16 segments and scoring wall
otion for each segment as 1 (normal), 2 (hypokinesis), 3 (akine-
is), or 4 (dyskinesis). The wall motion score index (WMSI) was
alculated as the sum of the scores of the segments divided by the
umber of segments evaluated. WMSI was calculated for segments
reated and not treated with cell implantation. LVEF was also
alculated by using an automatic border detection system.21 Re-
ional contractility was also assessed by color kinesis and tissue
oppler imaging for each segment. All studies were performed by
different observers. Reproducibility values within studies were
.8  6.4 mL (variation coefficient, 5.5%) for LV end-diastolic
olume and 0.3  4.6 (variation coefficient, 6.6%) for LVEF.
Tissue viability was assessed by low-dose dobutamine stress
chocardiography for which dobutamine was given intravenously
t an initial dose of 5 g · kg1 · min1 that was incremented
very 3 minutes at 5 g · kg1 · min1 until a maximal dose of
0 g · kg1 · min1 was achieved. A continuous electrocardio-
ram was recorded, and semiquantitative regional function was
lindly analyzed.
ET Studies
yocardial blood flow and glucose metabolism were measured by
ET scans before treatment and 3 and 12 months after treatment.
he perfusion and metabolism studies were performed with a
hole-body PET (ECAT EXACT HR; Siemens/CTI, Knoxville,
enn) as previously described.19
l 2006
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Putologous Skeletal Myoblast Cell Culture
hree to 4 weeks before CABG surgery, a muscle biopsy was
btained from the vastus lateralis under sterile conditions with the
atient under local anesthesia (2% lidocaine hydrochloride) and
rocessed immediately to obtain muscle progenitor cells as previ-
usly described.8,19 All patients underwent a plasma exchange the
ay before muscle biopsy was performed by using heparin as an
nticoagulant. Cell cultures were incubated at 37°C and 5% carbon
ioxide, and passage of the culture was performed at subconflu-
nce to prevent myotube formation. During the first passage,
replating was applied to eliminate contamination of myoblasts
ith fibroblasts. Myoblasts were harvested after 3 to 4 passages for
mplantation. Myoblast purity was measured by flow cytometry
fter staining with monoclonal antibodies against human N-CAM
CD56), CD45, and desmin.22
ABG Surgery and Cell Implantation
hree to 4 weeks after muscle biopsy, all patients underwent
onventional aortocoronary bypass surgery. During cardiopulmo-
ary bypass and after the conclusion of all graft anastomoses,
mmediately before removing extracorporeal circulation and while
he heart was initiating spontaneous heartbeats, muscle progenitor
ells (myoblasts) were injected subepicardially by multiple injec-
ions with an angled needle (Steriseal Opthalmic canula, 23 gauge;
aersk Medical Ltd Redditch, UK) that allows tangential injection
f cells under the epicardium. Myoblasts were implanted in seg-
ents previously identified by echocardiography as akinetic or
yskinetic in and around the infarct. Areas receiving cells were
dentified before surgery by echocardiogram, and these same areas
ere analyzed during follow-up to determine changes in regional
ontractility. Before myoblast implantation, a sample of the har-
ested myoblasts was used for microbiology cultures, including
ram staining to determine culture contamination. All patients
ere monitored with continuous telemetry throughout their hos-
ital stay.
tatistical Analysis
tatistical analysis was performed with the SPSS 10.0 for Windows
oftware package (SPSS Inc, Chicago, Ill). The normal distribution
f quantitative variables was examined with the Kolmogorov-
mirnov test with the Lilliefors correction. Comparisons were
erformed with the paired t test for dependent variables and the
ilcoxon rank sum test, depending on the normality test. Differ-
nces between groups were analyzed with the 2 test (qualitative
ariables) or the t test for independent samples (quantitative vari-
bles). Comparisons for repeated measurements were performed
ith analysis of variance or the Friedman test. Descriptive analysis
s presented as mean (SEM) for quantitative variables or median
interquartile range) for categorical variables.
esults
total of 12 patients (11 men and 1 woman) with a mean
ge of 64.5 years (3.2 years) were included. Two patients
ere excluded from the analysis according to the criteria
efined by the protocol (in 1 patient, myoblasts could not be
ultured, and in another patient, the Gram staining before
mplantation was positive). The control group included 14 (
The Journal of Thoracicatients who had undergone CABG. There were no statis-
ically significant differences between the characteristics of
oth groups (Tables E1 and E2).
All patients underwent CABG as scheduled. The infarct
rea was documented as nonviable by dobutamine echocar-
iography and 18F-FDG PET in patients undergoing myo-
last transplantation (viability was assessed only by dobut-
mine echocardiography in the control group). The mean
ize of the muscle biopsy was 9.45 g (5.5-14 g), and the
ean volume of autologous serum obtained was 1.735 mL
800-2.135 mL). After a median of 23 days (18-26 days) in
ulture, a mean of 221  106 (105-390  106) myoblasts
ere obtained with a purity of 65.6% (48%-92%; percent-
ge of CD56 cells/CD45 cells). An average of 5 mL
3.5-6 mL) of solution containing skeletal myoblasts was
njected by multiple injections as previously described.19
he average concentration of myoblasts was 50  106/mL,
nd the number of injections varied between 5 and 15. The
edian number of segments treated with myoblasts was 7
4-10): anterior wall, n  6; inferior wall, n  3; and apical
egion, n  1. No significant differences were found be-
ween patients and controls regarding the surgical procedure
Table E2).
dverse Events
n the group of patients treated with myoblasts, 2 patients
ere readmitted to the hospital with heart failure: 1 at 5
onths after surgery and 1 at 12 months after surgery, also
aving recurrence of angina. One patient had episodes of
aroxystic third-degree atrioventricular block requiring pace-
aker implantation 5 months after surgery. Before surgery,
octurnal episodes of complete atrioventricular block were
etected in this patient by Holter monitoring. Finally, amyo-
rophic lateral sclerosis developed in 1 patient 6 months
fter surgery. The median number of ventricular premature
eats was 13 (309), 11 (23), and 34 (759) at baseline and 3
nd 12 months, respectively (P .386). No other malignant
rrhythmias were detected, and no implantable defibrillators
ere required. Plasma exchange was not associated with
dverse events. Muscle biopsy was associated with a minor
ocal bleeding episode in 1 patient 12 hours after the biopsy.
In the control group, 4 patients experienced heart failure
nd were readmitted to the hospital. Two of them were
reated with a resynchronization pacemaker, in 1 case with
nternal defibrillator capabilities.
chocardiography Results
t 12 months after surgery, a significant increase in LVEF
nd a decrease in LV diameters and volumes were observed
Table E3). LVEF by automatic border detection increased
rom 40.38% (2.42%) at baseline to 54.33% (2.46%) and
0.83 (3.5%) at 3 and 12 months after surgery, respectively
P .001). Both at 3 and 12 months, there was a significant
and Cardiovascular Surgery ● Volume 131, Number 4 801
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CSPmprovement in regional contractility assessed by WMSI in
he group of patients treated with myoblast implantation. A
tatistically significant improvement was observed when we
nalyzed segments treated with revascularization alone or
ith revascularization and skeletal myoblasts (Table 1).
In the control group, the increase in LVEF 12 months
fter surgery did not reach statistical significance, and no
ignificant changes were detected in remodeling parameters
r in the WMSI (Tables 1 and E3). The changes in LVEF
nd in LV diameters were significantly different between
he group of patients treated with myoblasts and the control
roup (Figures 1 and 2).
yocardial Perfusion and Viability PET Studies
he 18F-FDG and 13N-ammonia PET were performed be-
ore surgery (1-5 days) and at 3 and 12 months after surgery.
 global increase in 18F-FDG uptake was observed at 3 and
2 months after surgery compared with baseline values.
his increase was more pronounced when only segments
reated with myoblasts were analyzed. Perfusion studies
ith 13N-ammonia showed a statistically significant im-
ABLE 1. Regional contractility studies (WMSI)
ariable Baseline 3 mo 12 mo P value
lobal
Control 2.1 (0.51) 2.02 (0.40) .620
Myoblasts 1.8 (0.14) 1.25 (0.08)* 1.15 (0.05) .001
reated segments
Control 2.99 (0.31) 2.82 (0.30) .220
Myoblasts 3.02 (0.17) 1.64 (0.16)* 1.36 (0.14) .001
ntreated segments
Control 1.65 (0.50) 1.55 (0.4) .425
Myoblasts 1.29 (0.08) 1.05 (0.04)* 1.02 (0.01) .041
ata are mean (SEM). WMSI, Wall motion score index. *P  .05 between
aseline and 3 months. There were no differences between 3 and 12
onths.
Figure 1. LVEF before and 12 months after CABG in p
Results represent individual values for each patient
observed in the control group and patients treated with my
02 The Journal of Thoracic and Cardiovascular Surgery ● Aprirovement at 12 months but not at 3 months. As described
n the viability studies, the improvement was particularly
bserved in segments treated with myoblasts (Table 2).
iscussion
he results of our study indicate that transplantation of
utologous skeletal myoblasts in patients with a history of
I as adjuvant therapy to bypass surgery is feasible and
afe and is associated with an improvement in LVEF and an
ncrease in the viability and perfusion of the nonviable
yocardium. This improvement appears mainly in the area
f implantation, as indicated by 18F-FDG and 13N-ammonia
ET.
nts treated with myoblasts and in the control group.
ell as the mean (SEM). P < .001 between changes
igure 2. Median percentage of change in LV diameters and
olumes in the group of patients treated with myoblasts and in the
ontrol group. LVEDV, Left ventricular end-diastolic volume;
VESV, left ventricular end-systolic volume; LVEDD, left ventric-
lar end-diastolic diameter; LVESD, left ventricular end-systolic
iameter.atie
as woblasts.
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CS
PIt has been demonstrated in small- and large-animal
odels of MI that skeletal myoblasts transplanted into the
yocardium are able to engraft and differentiate into myo-
bers and, under certain circumstances, may acquire char-
cteristics of cardiomyocytes (see review15). In the clinical
etting, transplantation of skeletal myoblast results in cell
ngraftment and contributes to improvement of cardiac
unction in patients with MI.17,18 However, despite a large
umber of studies, the mechanisms by which myoblasts
ontribute to cardiac function remain unknown. Some stud-
es have suggested that myoblasts acquire certain character-
stics of cardiac muscle after transplantation into the myo-
ardium (presence of cardiac-specific myosin heavy chain
nd connexin 43).23 Moreover, at least in vitro, skeletal
bers and cardiac muscle can form electromechanical junc-
ions.24 Nevertheless, overwhelming evidence indicates that
keletal myoblasts do not transdifferentiate into cardiomy-
cytes.25,26 The elastic properties of implanted fibers and/or
he secretion of certain growth or survival factors, contrib-
ting to remodeling or to recruitment of circulating or local
ardiac stem cells, have been implicated as potential mech-
nisms involved in the observed benefit of myoblast trans-
lantation in animal studies.15
The number of skeletal myoblasts transplanted in the
ifferent studies have varied from a few million to more
han a billion cells.17,18 On the basis of preclinical data
uggesting that functional improvement is correlated with
he number of cells27 and the fact that myoblast retention
fter transplantation is less than 5%,28 the number of cells
njected in our study could be considered to be in the lower
ange. However, the number of cells injected in our patients
as similar to the number of cells injected in 2 other studies
n which engraftment of myoblasts was demonstrated.18,29
lthough proof of engraftment was not obtained in our
atients, the results of these studies and the increase in
ABLE 2. Myocardial viability and perfusion studies (PET)
ariable Baseline 3 mo 12 mo P value
lobal
Ammonia 0.47 0.03 0.50 0.02 0.65 0.06 .019
18F-FDG 0.158 0.02 0.270 0.01* 0.267 0.02 .019
reated
segments
Ammonia 0.40 0.05 0.44 0.03 0.62 0.05† .009
18F-FDG 0.126 0.02 0.231 0.01* 0.230 0.02 .004
ntreated
segments
Ammonia 0.59 0.05 0.62 0.04 0.67 0.07 .215
18F-FDG 0.170 0.05 0.284 0.01* 0.280 0.05 .930
ET, Positron emission tomography; 18F-FDG, fluorine 18–fluorodeoxyglucose.
P  .05 between baseline and 3 months. †P  .05 between 3 and 12
onths.8F-FDG uptake in the area where the cells had been im- t
The Journal of Thoraciclanted suggest that probably enough cells were injected to
btain a successful engraftment.
The functional improvement observed in our patients is
ncouraging but is certainly overshadowed by the fact that
atients underwent both skeletal myoblast transplantation
nd bypass surgery to the same area that received cells. This
s a major limitation of our study. As we have described,
everal approaches have been used to try to differentiate the
unctional benefit derived from myoblast transplantation
rom the potential effect of bypass surgery. Although the
alue of using a control group for comparison is limited and
nly randomized trials can establish whether the improve-
ent in cardiac function is due to cell therapy, the results of
he comparison between patients and controls clearly sug-
est that transplantation of myoblasts is associated with an
ncrease in LVEF for up to 1 year after surgery. Further-
ore, the differences observed in end-systolic and end-
iastolic diameters suggest that skeletal myoblasts could
imit ventricular remodeling, probably by releasing mole-
ules capable of altering the extracellular matrix.30 The lack
f uptake of 18F-FDG PET as an inclusion criterion ex-
ludes the possibility that improved cardiac function could
e due to revascularization of hibernating tissue. Also, the
ncrease in 18F-FDG uptake mainly in areas where myo-
lasts were injected, along with the improvement in WMSI
n the same areas, suggests that the benefit observed is, at
east in part, due to the injected myoblasts.
It is interesting to note that a statistically significant
ncrease in the uptake of 13N-ammonia was observed 12
onths after surgery and that this was more pronounced in
reas where myoblasts had been implanted. As described
reviously, increased perfusion is associated with increased
3N-ammonia uptake, and this suggests an increase in vas-
ularization of the infarct area. Although histological anal-
sis would be required to demonstrate an increase in angio-
enesis or vasculogenesis in patients who have undergone
ransplantation with myoblasts, these results suggest that
his mechanism may underlie the benefit observed in our
atients. In a recent study in patients receiving skeletal
yoblast transplants at the time of LV assist device implan-
ation, the morphological analysis suggested an increase in
ngiogenesis in the explanted heart at the time of heart
ransplantation.18
An important finding in our patients is the lack of cardiac
rrhythmias observed—a finding that contrasted with other
ecent studies,17,18 in which 4 of 10 patients with old MIs
reated with CABG and intramyocardial injection of skeletal
yoblasts required implantation of an automatic internal
ardioverter-defibrillator.17 The reason for these arrhyth-
ias is at present unknown, but it could be related to
lectrical reentry circuits due to the lack of established gap
unctions between skeletal myoblasts and cardiomyocytes,25
o the number and/or volume of cells implanted, or to other
and Cardiovascular Surgery ● Volume 131, Number 4 803
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CSPurrently unknown mechanisms. We cannot rule out that the
bsence of arrhythmias in our patients is not due to revas-
ularization of the infarct area, to the use of autologous
erum (the use of bovine serum in cell cultures has been
ssociated with inflammation and/or killing of the cells31),
r even to patient selection, because the baseline LVEF was
etter in our patients than in either of the previous stud-
es.17,18 In a very recent study, the finding that skeletal
yoblasts do not establish gap junctions with cardiomyo-
ytes has been hypothesized as a mechanism to prevent the
eneration of dangerous premature beats26: this is consistent
ith our own clinical observations.
In conclusion, our results suggest that cell transplantation
ith bypass surgery is associated with improved cardiac
unction, increased tissue viability, and lack of side effects,
hus resulting in a promising therapy for patients with heart
ailure. These results warrant further clinical research, in-
luding randomized studies.
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PTABLE E1. Baseline characteristics of patients and con
trols
Variable Myoblast group Controls P value
n 10 14
Age (y) 64.5 (3.3) 60.4 (9.5) .321
Male 9 (90%) 12 (85.7%) .754
Concurrent risk factors
Hypertension 4 (40%) 7 (50%) .697
Diabetes mellitus 3 (30%) 6 (42%) .889
Hyperlipidemia 4 (40%) 8 (57.1%) .889
Current cigarette use 9 (90%) 8 (57.1%) .172
Infarct-related artery
Left anterior descending 7 (70%) 6 (42.9%) .240
Right coronary 3 (30%) 8 (57.1%) .240
Primary therapy for MI
Fibrinolysis 6 (60%) 4 (28.6%) .211
Angioplasty 2 (20%) 9 (64.3%) .051
Medical therapy 2 (20%) 1(7.1%) .550
Time from MI to CABG (mo) 21.5 (118) 19.9 (23) .136
Echocardiographic data
LVEF 35.6 (2.3) 33.4 (9.1) .328
LVEDV 175 (39.3) 221 (101) .167
LVESV 99.1 (26.8) 141 (68.3) .087
LVEDD 60.8 (4.1) 65 (12.4) .441
LVESD 45.7 (5.4) 50.8 (12.2) .319
Current therapy
ACEI/ARB 10 (100%) 10 (71.4%) .678
ASA 10 (100%) 14 (100%) 0.889
-blockers 7 (70%) 8 (57.1%) .388
Statins 10 (100%) 9 (65%) .053
Diuretics 7 (70%) 9 (65%) .678
Data are n (%) or mean (SEM). MI, Myocardial infarction; CABG, coronar
artery bypass grafting; ACEI, angiotensin-converting enzyme inhibitor
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastoli
volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricula
end-diastolic diameter; LVESD, left ventricular end-systolic diameter; ARB
angiotensin receptor blocker; ASA, acetylsalicylic acid.-
y
;
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,TABLE E2. Surgical data of patients and controls
Variable Myoblast group Controls P value
No. grafts
2 2 (20) 1 (7.1) .550
3 4 (40) 7 (50) .280
3 4 (40) 6 (42.9) .211
Revascularization to infarct area 9 (90) 13 (92) 0.786
Aneurysmectomy 1 (10) 1 (7.1) 0.926
Bypass duration 128.9 (18.5) 157 (64.2) .298
Maximal CK levels (UI/L) 806 (127.3) 782 (575) .882
Maximal CK-MB levels (UI/L) 26.9 (2.7) 35.7 (38.1) .433
Maximal troponin levels (ng/mL) 2.86 (1.85) 4.77 (4.7) .347
Data are mean (SEM). CK, Creatine kinase; CK-MB, creatinine kinase
isoenzyme MB.
The Journal of Thoracic anTABLE E3. Echocardiographic results
Variable Baseline 12 mo P value
LVEF
Control 33.6 (9.3) 38.6 (11) .08
Myoblasts 35.6 (5.6) 55.1 (8.2) .01
LVEDV
Control 221 (101,6) 223 (64.1) .91
Myoblasts 175 (39.3) 166.1 (30) .63
LVESV
Control 141 (68.3) 125 (55.8) .36
Myoblasts 99.1 (26.8) 69.1 (15.8) .01
LVEDD
Control 65 (12.4) 65.8 (12.1) .69
Myoblasts 60.8 (4.1) 53.5 (3.2) .01
LVESD
Control 50.8 (12.2) 50.5 (11.9) .89
Myoblasts 45.75 (5.4) 38.6 (3.5) .01
Data are mean (SEM). LVEF, Left ventricular ejection fraction; LVEDV, left
ventricular end-diastolic volume; LVESV, left ventricular end-systolic vol-
ume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventriculard Cardiovascular Surgery ● Volume 131, Number 4 804.e1
